SCM
CSTL icon

Sterling Capital Management’s Castle Biosciences CSTL Stock Holding History

Sterling Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8K Sell
971
-666
-41% -$21.8K ﹤0.01% 1955
2025
Q4 		$63.7K Sell
1,637
-323
-16% -$10.4K ﹤0.01% 1711
2025
Q3 		$44.6K Buy
1,960
+1,193
+156% +$24.2K ﹤0.01% 1790
2025
Q2 		$15.7K Buy
767
+451
+143% +$8.35K ﹤0.01% 1885
2025
Q1 		$6.33K Sell
316
-256
-45% -$6.34K ﹤0.01% 2040
2024
Q4 		$15.2K Buy
572
+500
+694% +$15.2K ﹤0.01% 1970
2024
Q3 		$2.05K Buy
+72
New +$1.83K ﹤0.01% 2173

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's CSTL Position: Q1 2026 in Review

Sterling Capital Management reduced its Castle Biosciences (CSTL) stake by 41% in Q1 2026, selling an estimated $21.8K and leaving 971 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Sterling Capital Management first reported a position in CSTL in Q3 2024 and has held it in 7 quarters since. The position peaked at $63.7K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Sterling Capital Management held 971 shares of Castle Biosciences worth $23.8K as of Q1 2026.
  • Sterling Capital Management sold 666 Castle Biosciences shares in Q1 2026, an estimated $21.8K.
  • Castle Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1955 holding.
  • Sterling Capital Management first reported a position in Castle Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Castle Biosciences position peaked at $63.7K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.